Alzheimer’s drug hailed as momentous breakthrough

ENGLAND: The first drug to slow the destruction of the brain in Alzheimer’s has been heralded as momentous.

The research breakthrough ends decades of failure and shows a new era of drugs to treat Alzheimer’s — the most common form of dementia — is possible.

Yet the medicine, lecanemab, has only a small effect and its impact on people’s daily lives is debated.

And the drug works in the early stages of the disease, so most would miss out without a revolution in spotting it.

Lecanemab attacks the sticky gunge — called beta amyloid — that builds up in the brains of people with Alzheimer’s.

For a medical field littered with duds, despair and disappointment, some see these trial results as a triumphant turning point. Alzheimer’s Research UK said the findings were “momentous”.

One of the world’s leading researchers behind the whole idea of targeting amyloid 30 years ago, Prof John Hardy, said it was “historic” and was optimistic “we’re seeing the beginning of Alzheimer’s therapies.”

Prof Tara Spires-Jones, from the University of Edinburgh, said the results were “a big deal, because we’ve had a 100 percent failure rate for a long time.”

Currently, people with Alzheimer’s are given other drugs to help manage their symptoms, but none change the course of the disease.

Lecanemab is an antibody — like those the body makes to attack viruses or bacteria — that has been engineered to conduct hearings on AGP report for procurement of Covid-related supplies and social payments made in FY20 and would give recommendations and referrals for investigation, as appropriate.

The AGP completed audit reports of key government agencies for FY21 (which included Covid-related spending and social payments). The audit reports on the procurement of Covid-related supplies are expected to be published by end-August 2022. It was stated in the letter that they asked the AGP to conduct special audits including SSGCL, Hesco and Pesco. The AGP said that as discussed in a meeting held on 22.11.2022, the special audit of SSGCL, HESCO and PESCO was considered at the appropriate level. “It is informed that these entities are being audited regularly every year with coverage of significant risk areas.” Furthermore, a thematic audit of the quality of services delivery by gas utility

to tell the immune system to clear amyloid from the brain.

Amyloid is a protein that clumps together in the spaces between neurons in the brain and forms distinctive plaques that are one of the hallmarks of Alzheimer’s. The large-scale trial involved 1,795 volunteers with early stage Alzheimer’s. Infusions of lecanemab were given every fortnight. The results, presented at the Clinical Trials on Alzheimer’s Disease conference in San Francisco and published in the New England Journal of Medicine, are not a miracle cure. The disease continued to rob people of their brain power, but that decline was slowed by around a quarter over the course of the 18 months of treatment. The data is already being assessed by regulators in the US who will soon decide whether lecanemab can be approved for wider use. The developers -- the pharmaceutical companies -- plan to begin the approval process in other countries next year.